10.1021/acs.jproteome.0c00646 196
KDIGO supports the use of GLP-1RAs for people with CKD and T2D and/or obesity
Patients can be treated not as passive recipients of a magic shot, but as active participants in their health journey with coaching, tools, and a tailored treatment plan that meets them where they are
To address the problem of once-a-day injections of Liraglutide, Lilly launched Dulaglutide, which is administered once a week and was approved by the FDA in 2014 for the treatment of type 2 diabetes
These effects of high-protein eating help explain why protein for weight management remains a consistent focus across many approaches to GLP-1 weight loss
Quick Answer: GLP-1 receptor agonists produce modest reductions in total cholesterol, LDL cholesterol, and triglycerides, though they are not primarily indicated for cholesterol management